Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Recruiting 9Completed 9Not yet recruiting 8Active not recruiting 3Unknown 1Terminated 1Approved for marketing 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Sarcoma 2

Conditions

Small Cell Lung Carcinoma 3

Interventions

Carboplatin 134pembrolizumab 113Pemetrexed 94Cisplatin 88durvalumab 62Paclitaxel 60osimertinib 54Nivolumab 54Docetaxel 44atezolizumab 41Etoposide 30Radiotherapy 28Radiosurgery 26Gemcitabine 26Specimen Handling 24Ipilimumab 23Taxes 19Magnetic Resonance Spectroscopy 19amivantamab 16130-nm albumin-bound paclitaxel 16Drug Therapy 15Bevacizumab 15Radiation 14Platinum 14Immunoglobulin G 14Disulfides 14cemiplimab 13Crizotinib 13Cyclophosphamide 12Biopsy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × PM 01183 × Thoracic × Clear all
NCT04802174 2026-03-17

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
37 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT05091567 2026-03-10

IMforte

Hoffmann-La Roche

Phase 3 Active not recruiting
660 enrolled 23 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT05740566 2026-01-05

DeLLphi-304

Amgen

Phase 3 Active not recruiting
509 enrolled 11 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡